Masitinib in Patients With Symptomatic Mild to Moderate COVID-19

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The objective of the study is to evaluate the anti-viral efficacy of 3 different dosages of masitinib in patients with symptomatic mild to moderate COVID-19.
Epistemonikos ID: 152a8e30666644f8c559d08498c98ec8548899e0
First added on: Sep 18, 2021